The company's cash burn and reliance on dilutive financing (warrant inducement) are the key risks. With only $954K cash and a stated need for additional funding, monitor for a potential equity offering or strategic transaction. The 18% Zola volume growth is a positive signal but insufficient to offset the deteriorating financial profile.
Price Chart
Executive Summary
Arcadia Biosciences reported Q1 2026 revenue of $1.1M, down 8% YoY from $1.2M, and a net loss of $4.4M ($2.11/share) vs net income of $2.6M ($1.90/share) in Q1 2025. The revenue decline was driven by a $193K revenue reserve release in the prior year, while the net loss was primarily due to a $2.9M loss on the January 2026 warrant inducement offer and $1.5M in other losses. Zola coconut water volumes grew 18% YoY and SG&A hit a record low, but the headline financials deteriorated sharply.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $1.1M, down 8% YoY from $1.2M
- Net loss attributable to common stockholders $4.4M ($2.11/share) vs net income $2.6M ($1.90/share) in Q1 2025
- Loss on January 2026 warrant inducement offer: $2.9M
- Other loss, net: $1.5M
- SG&A decreased 32% YoY to $1.18M, lowest in company history
- Zola coconut water unit volumes increased 18% YoY
- Cash and cash equivalents $954K at March 31, 2026, up from $259K at Dec 31, 2025
- Company states it will require additional funding in the near future
- Gross proceeds of ~$2.1M from exercise of preferred investment options
Financial Impact
Revenue declined $100K (8% YoY); net income swung from +$2.6M to -$4.4M, a $7.0M deterioration driven by $2.9M warrant inducement loss and $1.5M other losses
Risk Factors
- Requires additional funding in the near future; risk of dilutive equity issuance
- Net loss of $4.4M on only $1.1M revenue indicates unsustainable cash burn
- Revenue decline of 8% YoY despite volume growth, due to prior-year reserve release
- Micro-cap with $2M market cap; extreme volatility and liquidity risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-223985 |
| Document: 0001193125-26-223985-index.html | 0001193125-26-223985 |
| Document: 0001193125-26-223985.txt | 0001193125-26-223985 |
| 8-K Data (Synthetic) | 0001193125-26-223985 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | SC 13G | $0.2800 | awaiting T+60 | — | $0.1518 (−45.79%) |
Sep 15, 2026 5w ago | 8-K | $0.4310 | awaiting T+60 | — | $0.1518 (−64.78%) |
Jul 9, 2026 15w ago | EFFECT | $0.6755 $0.2882 | ▲ +57.34% | ▲ +58.97% | $0.1518 (+77.53%) |
Jul 2, 2026 16w ago | 8-K | $0.7330 $0.3080 | ▼ −57.98% | ▼ −61.55% | $0.1518 (−79.29%) |
Jun 26, 2026 17w ago | S-3 | $0.7190 $0.4480 | ▲ +37.69% | ▲ +42.08% | $0.1518 (+78.89%) |
Jun 15, 2026 19w ago | 8-K | $0.9183 $0.4797 | ▲ +47.76% | ▲ +48.77% | $0.1518 (+83.47%) |
Jun 12, 2026 19w ago | Press Release | $0.9183 $0.4797 | ▲ +47.76% | ▲ +48.77% | $0.1518 (+83.47%) |
Jun 12, 2026 19w ago | Press Release | $0.9180 $0.4530 | ▲ +50.65% | ▲ +51.31% | $0.1518 (+83.46%) |
May 14, 2026 23w ago | 8-K | $0.9560 $0.6699 | ▲ +29.93% | ▲ +34.44% | $0.1518 (+84.12%) |
Apr 30, 2026 25w ago | 10-K/A | $1.12 $0.6300 | ▼ −43.75% | ▼ −46.82% | $0.1518 (−86.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers